ClinicalTrials.gg
Status unknownNCT03237442Updated Aug 2, 2017

Umbilical Cord Mesenchymal Stem Cells Injection for Ocular Corneal Burn

A Phase 1/2 interventional study of human umbilical cord mesenchymal stem cells and placebo in Ocular Corneal Burn, sponsored by Guangzhou Saliai Stem Cell Science and Technology Co. Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-08-02.

Sponsored by Guangzhou Saliai Stem Cell Science and Technology Co. Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Burns with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Burns · China.

Planned enrollment
6th of 20
100 · median 67
Started
2018
with 1 other
Phase 1/2
4 of 24
2 open now
Registered
6th of 24
by date
Lead sponsor
1 of 24
Guangzhou Saliai Stem Cell Science and Technology Co. Ltd.

Among the 24 studies in Burns with a site in China, this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2018, is one of 4 in phase 1/2, and was the 6th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

10 of the 24 studies in Burns with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 85 Burns studies recruiting now, 38 (45%) set no upper age limit and 38 (45%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Burns with a site in China, or all of them as a file.
02

Study summary

Ocular chemical burn is one of the causes of vision loss in China, and there are no satisfactory treatment. Human umbilical cord mesenchymal stem cells(UC-MSCs) have the biological characteristics of self-renewal, immune regulation, multidirectional differentiation and tissue repair. Our preliminary research showed that in corneal alkali injury rabbits, the UC-MSCs can accelerated the cornea repair, inhibited angiogenesis. The aim of this study is to access the efficacy and safety of UC-MSCs in the treatment of corneal burn in human.

03

Conditions studied

  • Ocular Corneal Burn

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • must be ocular burns including chemically burned or the thermally burned;
  • the subjects are willing to accept this research, and promise to coordinate with the researchers during the follow up period;
  • the subjects should abide by the laws and rules of the study.

Exclusion criteria

Exclusion Criteria:

  • the visual acuity is blind in any of the eye;
  • have corneal perforation or have the corneal perforation tendency;
  • have been accepted surgery on eyeball after trauma;
  • IOP>=25 mmHg even after antiglaucoma;
  • have the history of other corneal disease or surgery;
  • have the history of radiotherapy or surgery in the eyeball;
  • associated with corneal ulcer or endoophthalmitis;
  • uncontrolled hypertension(>=150/95 mmHg);
  • abnormal liver and renal function;
  • the pregnant women.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    group 1

    Biological: human umbilical cord mesenchymal stem cells

  • Active comparator
    group 2

    Biological: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. the percent of cornea perforation

    Time frame: 3 months

07

Study locations

1 site
  • The First Affiliated Hospital of Jinan University
    Guangzhou, Guangdong, China
    • Yanyan Ma · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2018; primary completion for Dec 2018, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2017
First posted
Aug 2, 2017
StartEst.
Jan 1, 2018
Primary completionEst.
Dec 30, 2018
CompletionEst.
Jun 30, 2019
Last update
Aug 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03237442
Lead sponsor
Guangzhou Saliai Stem Cell Science and Technology Co. Ltd.
Responsible party
Sponsor
First posted
Aug 2, 2017
Start date
Jan 1, 2018 (estimated)
Primary completion
Dec 30, 2018 (estimated)
Completion
Jun 30, 2019 (estimated)
Last update
Aug 2, 2017

Study contacts

Wanling Chen
Contact
chenwanling@saliai.com
0086-20-37792600

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion